{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:24:28Z","timestamp":1787027068438,"version":"build-2736575974"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    Lapatinib is an FDA-approved EGFR and HER2 tyrosine kinase inhibitor for the treatment of HER2-positive breast cancer patients. However, its therapeutic efficacy is limited by primary or acquired resistance. In the present study, we established breast cancers cells with acquired lapatinib resistance and investigated the antitumor activity of the second-generation HSP90 inhibitor ganetespib in association with lapatinib in lapatinib-sensitive and -resistant cells. The combination treatment showed synergistic inhibition of HER and the downstream PI3K\/Akt and Ras\/MEK\/ERK pathways, in addition to enhancing induction of early apoptotic cell death and G1 arrest in both parent and lapatinib-resistant cells\n                    <jats:italic>in vitro<\/jats:italic>\n                    . The joint administration of ganetespib and lapatinib depleted the aberrant nuclear transcription factor STAT3, a mediator of the cell cycle and apoptosis-related pathways that is probably involved in the lapatinib resistance of HER2-positive breast cancer cells. In conjunctive with the augmented inhibition of tumor growth observed in both SKBR3 and SKBR3-L xenografts compared to monotherapy, our data provide a sound preclinical basis for combination treatment with lapatinib and ganetespib for refractory HER2-positive breast cancer.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2021.651516","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:57:01Z","timestamp":1625446621000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells"],"prefix":"10.3389","volume":"12","author":[{"given":"Min","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingli","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaole","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1101\/gad.914401","article-title":"Cell Cycle Checkpoint Signaling through the ATM and ATR Kinases","volume":"15","author":"Abraham","year":"2001","journal-title":"Genes Dev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ccr.2014.02.025","article-title":"ERBB Receptors: from Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics","volume":"25","author":"Arteaga","year":"2014","journal-title":"Cancer Cell"},{"key":"B3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/nrclinonc.2011.177","article-title":"Treatment of HER2-Positive Breast Cancer: Current Status and Future Perspectives","volume":"9","author":"Arteaga","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1158\/1078-0432.CCR-08-0132","article-title":"Heat Shock Protein 90 as a Drug Target: Some like it Hot","volume":"15","author":"Banerji","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0140-6736(11)61847-3","article-title":"Lapatinib with Trastuzumab for HER2-Positive Early Breast Cancer (NeoALTTO): a Randomised, Open-Label, Multicentre, Phase 3 Trial","volume":"379","author":"Baselga","year":"2012","journal-title":"The Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/annonc\/mdn759","article-title":"Single-agent Lapatinib for HER2-Overexpressing Advanced or Metastatic Breast Cancer that Progressed on First- or Second-Line Trastuzumab-Containing Regimens","volume":"20","author":"Blackwell","year":"2009","journal-title":"Ann. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","article-title":"Randomized Study of Lapatinib Alone or in Combination with Trastuzumab in Women with ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer","volume":"28","author":"Blackwell","year":"2010","journal-title":"Jco"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5595","DOI":"10.1038\/sj.onc.1204595","article-title":"Translocations Involving C-Myc and C-Myc Function","volume":"20","author":"Boxer","year":"2001","journal-title":"Oncogene"},{"key":"B9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.critrevonc.2010.04.012","article-title":"Resistance to HER2 Inhibitors: Is Addition Better Than Substitution? Rationale for the Hypothetical Concept of Drug Sedimentation","volume":"78","author":"Campone","year":"2011","journal-title":"Crit. Rev. Oncology\/Hematology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.18632\/oncotarget.1148","article-title":"Neratinib Overcomes Trastuzumab Resistance in HER2 Amplified Breast Cancer","volume":"4","author":"Canonici","year":"2013","journal-title":"Oncotarget"},{"key":"B11","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/s1097-2765(01)00320-3","article-title":"BCL-2, BCL-XL Sequester BH3 Domain-Only Molecules Preventing BAX- and BAK-Mediated Mitochondrial Apoptosis","volume":"8","author":"Cheng","year":"2001","journal-title":"Mol. Cel"},{"key":"B12","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nrm1962","article-title":"EGF-ERBB Signalling: towards the Systems Level","volume":"7","author":"Citri","year":"2006","journal-title":"Nat. Rev. Mol. Cel Biol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.4161\/cc.3.1.607","article-title":"The Achilles Heel of ErbB-2\/HER2: Regulation by the Hsp90 Chaperone Machine and Potential for Pharmacological Intervention","volume":"3","author":"Citri","year":"2004","journal-title":"Cell Cycle"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1158\/1541-7786.MCR-09-0313","article-title":"The Association and Nuclear Translocation of the PIAS3-STAT3 Complex Is Ligand and Time Dependent","volume":"7","author":"Dabir","year":"2009","journal-title":"Mol. Cancer Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.ctrv.2015.08.001","article-title":"Mechanisms of Lapatinib Resistance in HER2-Driven Breast Cancer","volume":"41","author":"D'Amato","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.breast.2012.04.002","article-title":"Breast Cancer and HSP90 Inhibitors: Is There a Role beyond the HER2-Positive Subtype?","volume":"21","author":"De Mattos-Arruda","year":"2012","journal-title":"The Breast"},{"key":"B18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10549-014-3250-x","article-title":"HER2-family Signalling Mechanisms, Clinical Implications and Targeting in Breast Cancer","volume":"149","author":"Elster","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"B19","doi-asserted-by":"publisher","first-page":"6350","DOI":"10.1016\/j.febslet.2005.10.020","article-title":"A Proteomic Snapshot of the Human Heat Shock Protein 90 Interactome","volume":"579","author":"Falsone","year":"2005","journal-title":"FEBS Lett."},{"key":"B20","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.breast.2013.11.011","article-title":"Treatment of HER2-Positive Breast Cancer","volume":"23","author":"Figueroa-Magalh\u00e3es","year":"2014","journal-title":"The Breast"},{"key":"B21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s10637-013-9971-6","article-title":"Targeted Inhibition of Hsp90 by Ganetespib Is Effective across a Broad Spectrum of Breast Cancer Subtypes","volume":"32","author":"Friedland","year":"2014","journal-title":"Invest. New Drugs"},{"key":"B22","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1158\/1078-0432.CCR-12-2024","article-title":"Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 Function","volume":"19","author":"Garrett","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib Plus Capecitabine for HER2-Positive Advanced Breast Cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/path.1335","article-title":"c-erbB-4\/HER4: Friend or Foe?","volume":"200","author":"Gullick","year":"2003","journal-title":"J. Pathol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/1476-4598-13-150","article-title":"FW-04-806 Inhibits Proliferation and Induces Apoptosis in Human Breast Cancer Cells by Binding to N-Terminus of Hsp90 and Disrupting Hsp90-Cdc37 Complex Formation","volume":"13","author":"Huang","year":"2014","journal-title":"Mol. Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.canlet.2014.10.040","article-title":"Novel Hsp90 Inhibitor FW-04-806 Displays Potent Antitumor Effects in HER2-Positive Breast Cancer Cells as a Single Agent or in Combination with Lapatinib","volume":"356","author":"Huang","year":"2015","journal-title":"Cancer Lett."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.4161\/cc.4.9.1985","article-title":"New and Old Functions of STAT3: A Pivitol Target for Individualized Treatment of Cancer","volume":"4","author":"Inghirami","year":"2005","journal-title":"Cell Cycle"},{"key":"B28","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s10549-012-2252-9","article-title":"PI3K Independent Activation of mTORC1 as a Target in Lapatinib-Resistant ERBB2+ Breast Cancer Cells","volume":"136","author":"Jegg","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"B29","doi-asserted-by":"publisher","first-page":"R33","DOI":"10.1186\/bcr1996","article-title":"NVP-AUY922: a Small Molecule HSP90 Inhibitor with Potent Antitumor Activity in Preclinical Breast Cancer Models","volume":"10","author":"Jensen","year":"2008","journal-title":"Breast Cancer Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.clbc.2013.12.012","article-title":"A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients with Metastatic Breast Cancer","volume":"14","author":"Jhaveri","year":"2014","journal-title":"Clin. Breast Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS15-P4-14-21","article-title":"Abstract P4-14-21: A Phase I Trial of Ganetespib (Heat Shock Protein 90 Inhibitor) in Combination with Paclitaxel and Trastuzumab in Patients with Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Metastatic Breast Cancer (MBC)","volume":"76","author":"Jhaveri","year":"2016","journal-title":"Cancer Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nature01913","article-title":"A High-Affinity Conformation of Hsp90 Confers Tumour Selectivity on Hsp90 Inhibitors","volume":"425","author":"Kamal","year":"2003","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.molmed.2004.04.006","article-title":"Therapeutic and Diagnostic Implications of Hsp90 Activation","volume":"10","author":"Kamal","year":"2004","journal-title":"Trends Mol. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1023\/a:1023785332315","article-title":"Regulators of G1 Cyclin-dependent Kinases and Cancers","volume":"22","author":"Lee","year":"2003","journal-title":"Cancer Metastasis Rev."},{"key":"B35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ccr.2014.05.019","article-title":"Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells","volume":"26","author":"Lee","year":"2014","journal-title":"Cancer Cell"},{"key":"B36","doi-asserted-by":"publisher","first-page":"5878","DOI":"10.1158\/0008-5472.CAN-08-0380","article-title":"A central Role for HER3 in HER2-Amplified Breast Cancer: Implications for Targeted Therapy","volume":"68","author":"Lee-Hoeflich","year":"2008","journal-title":"Cancer Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"5678","DOI":"10.18632\/oncotarget.3296","article-title":"Combining Lapatinib and Pertuzumab to Overcome Lapatinib Resistance Due to NRG1-Mediated Signalling in HER2-Amplified Breast Cancer","volume":"6","author":"Leung","year":"2015","journal-title":"Oncotarget"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1158\/1535-7163.MCT-13-0095","article-title":"Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non-small Cell Lung Cancer","volume":"12","author":"Li","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"B39","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.tcb.2006.10.008","article-title":"ErbB Receptors: New Insights on Mechanisms and Biology","volume":"16","author":"Linggi","year":"2006","journal-title":"Trends Cel Biol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"5410","DOI":"10.1200\/JCO.2007.11.7960","article-title":"Combination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) Is Safe and Active in Trastuzumab-Refractory HER-2-Overexpressing Breast Cancer: A Phase I Dose-Escalation Study","volume":"25","author":"Modi","year":"2007","journal-title":"Jco"},{"key":"B41","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/ncponc0509","article-title":"Mechanisms of Disease: Understanding Resistance to HER2-Targeted Therapy in Human Breast Cancer","volume":"3","author":"Nahta","year":"2006","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1158\/1535-7163.MCT-06-0423","article-title":"Lapatinib Induces Apoptosis in Trastuzumab-Resistant Breast Cancer Cells: Effects on Insulin-like Growth Factor I Signaling","volume":"6","author":"Nahta","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1021\/mp3002182","article-title":"Lapatinib and 17AAG Reduce 89Zr-Trastuzumab-F(ab\u2032)2 Uptake in SKBR3 Tumor Xenografts","volume":"9","author":"Oude Munnink","year":"2012","journal-title":"Mol. Pharmaceutics"},{"key":"B44","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3109\/00016489409126025","article-title":"The Detection of Thec-mycandrasOncogenes in Nasopharyngeal Carcinoma by Immunohistochemistry","volume":"114","author":"Porter","year":"1994","journal-title":"Acta Oto-Laryngologica"},{"key":"B45","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.str.2007.12.016","article-title":"Mechanism of Activation and Inhibition of the HER4\/ErbB4 Kinase","volume":"16","author":"Qiu","year":"2008","journal-title":"Structure"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.4161\/cbt.7.10.6585","article-title":"A Combination of Trastuzumab and 17-AAG Induces Enhanced Ubiquitinylation and Lysosomal Pathway-dependent ErbB2 Degradation and Cytotoxicity in ErbB2-Overexpressing Breast Cancer Cells","volume":"7","author":"Raja","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"B47","doi-asserted-by":"publisher","first-page":"7634","DOI":"10.1073\/pnas.93.15.7634","article-title":"Expression of Cyclin D1 in Epithelial Tissues of Transgenic Mice Results in Epidermal Hyperproliferation and Severe Thymic Hyperplasia","volume":"93","author":"Robles","year":"1996","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1158\/1535-7163.MCT-10-0966","article-title":"Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer","volume":"10","author":"Scaltriti","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"B49","doi-asserted-by":"publisher","first-page":"4986","DOI":"10.1158\/1078-0432.CCR-12-0792","article-title":"Targeting Stat3 Abrogates EGFR Inhibitor Resistance in Cancer","volume":"18","author":"Sen","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"15411","DOI":"10.1007\/s13277-016-5467-2","article-title":"Lapatinib Resistance in HER2+ Cancers: Latest Findings and New Concepts on Molecular Mechanisms","volume":"37","author":"Shi","year":"2016","journal-title":"Tumor Biol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.drudis.2007.10.007","article-title":"Development and Application of Hsp90 Inhibitors","volume":"13","author":"Solit","year":"2008","journal-title":"Drug Discov. Today"},{"key":"B52","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/08977190500178745","article-title":"Opposing Actions of STAT-1 and STAT-3","volume":"23","author":"Stephanou","year":"2005","journal-title":"Growth Factors"},{"key":"B53","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/nrc3559","article-title":"Targeting the ERBB Family in Cancer: Couples Therapy","volume":"13","author":"Tebbutt","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrc2887","article-title":"Targeting the Dynamic HSP90 Complex in Cancer","volume":"10","author":"Trepel","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"B55","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1158\/0008-5472.CAN-07-5115","article-title":"The EGFR-STAT3 Oncogenic Pathway Up-Regulates the Eme1 Endonuclease to Reduce DNA Damage after Topoisomerase I Inhibition","volume":"68","author":"Vigneron","year":"2008","journal-title":"Cancer Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"R121","DOI":"10.1186\/bcr3067","article-title":"Different Mechanisms for Resistance to Trastuzumab versus Lapatinib in HER2- Positive Breast Cancers - Role of Estrogen Receptor and HER2 Reactivation","volume":"13","author":"Wang","year":"2011","journal-title":"Breast Cancer Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3892\/ijo.2012.1568","article-title":"STAT3 Inhibition, a Novel Approach to Enhancing Targeted Therapy in Human Cancers","volume":"41","author":"Wang","year":"2012","journal-title":"Int. J. Oncol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"6255","DOI":"10.1038\/sj.onc.1205794","article-title":"Anti-tumor Activity of GW572016: a Dual Tyrosine Kinase Inhibitor Blocks EGF Activation of EGFR\/erbB2 and Downstream Erk1\/2 and AKT Pathways","volume":"21","author":"Xia","year":"2002","journal-title":"Oncogene"},{"key":"B59","doi-asserted-by":"publisher","first-page":"R85","DOI":"10.1186\/bcr3480","article-title":"An Heregulin-EGFR-HER3 Autocrine Signaling axis Can Mediate Acquired Lapatinib Resistance in HER2+ Breast Cancer Models","volume":"15","author":"Xia","year":"2013","journal-title":"Breast Cancer Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.14670\/HH-20.1005","article-title":"The Diverse Signaling Network of EGFR, HER2, HER3 and HER4 Tyrosine Kinase Receptors and the Consequences for Therapeutic Approaches","volume":"20","author":"Zaczek","year":"2005","journal-title":"Histol. Histopathol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.cell.2004.12.024","article-title":"Navigating the Chaperone Network: an Integrative Map of Physical and Genetic Interactions Mediated by the Hsp90 Chaperone","volume":"120","author":"Zhao","year":"2005","journal-title":"Cell"},{"key":"B62","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/35044005","article-title":"The DNA Damage Response: Putting Checkpoints in Perspective","volume":"408","author":"Zhou","year":"2000","journal-title":"Nature"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.651516\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:57:04Z","timestamp":1625446624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.651516\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":62,"alternative-id":["10.3389\/fphar.2021.651516"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.651516","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,5]]},"article-number":"651516"}}